290 patents
Page 2 of 15
Utility
Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
14 Nov 23
The invention provides a crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, methods of inhibiting tropomyosin-related kinase and/or c-FMS, and methods of treating medical diseases and conditions, such as pain.
Benoit Robert
Filed: 11 Nov 22
Utility
Hyperglycosylated binding polypeptides
7 Nov 23
Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering.
Clark Pan, Huawei Qiu, Pradeep Dhal, Bo Chen, Diego Gianolio
Filed: 17 Oct 19
Utility
Carboxylic Acid-containing Compounds As Modulators of Bis-phosphoglycerate Mutase for the Treatment of Sickle Cell Disease
2 Nov 23
Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.
Kunal Desai, Zhong Fang, Kevin Guertin, Vu Hong, John Ziqi Jiang, Sungtaek Lim, Mark Munson
Filed: 14 Sep 21
Utility
Compounds As Modulators of Bis-phosphoglycerate Mutase for the Treatment of Sickle Cell Disease
2 Nov 23
Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.
Kunal Desai, Zhong Fang, Kevin Guertin, Vu Hong, John Ziqi Jiang, Sungtaek Lim, Jinyu Liu, Mark Munson
Filed: 14 Sep 21
Utility
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
31 Oct 23
The present disclosure relates to antisense oligonucleotides (AONs) for modulating the expression of glycogen synthase.
Carol A. Nelson, Bruce M. Wentworth, Ronald K. Scheule, Timothy E. Weeden, Nicholas P. Clayton
Filed: 5 May 20
Utility
Perfusion Bioreactor With Filtration Systems
26 Oct 23
The disclosure provides a filtration system for a cell culture apparatus and a method of cell culture.
Jiuyi Lu, Jason Walther, Jonathan Wang, Kevin Victor Chen
Filed: 28 Apr 23
Utility
Methods for quantifying drug concentration in a prodrug composition
24 Oct 23
Methods for quantifying the amount of drug present in a crosslinked hyaluronic acid-linker-peptide (xHA-L-P) prodrug composition are provided.
Kim Alving, Bing Wang
Filed: 6 May 20
Utility
Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors
24 Oct 23
Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed.
Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
Filed: 20 Aug 21
Utility
Methods to Produce Rod-derived Cone Viability Factor (RDCVF)
12 Oct 23
The invention is related to methods of producing rod-derived cone viability factor (RdCVF).
Catherine R. O’RIORDAN, William H. BRONDYK
Filed: 14 Dec 22
Utility
Variant RNAi
10 Oct 23
Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence.
Lisa M. Stanek, Adam Palermo, Brenda Richards, Sergio Pablo Sardi, Catherine O′Riordan, Antonius Song
Filed: 28 Jul 20
Utility
Ultra-high Density Cell Banking Methods
5 Oct 23
Provided are methods for the creation of ultra-high density cryopreserved cell banks.
Xiaoxia Jin, Claudia Buser
Filed: 23 Feb 23
Utility
FGFR3 Antibodies and Methods of Use
28 Sep 23
Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided.
Yves SABBAGH, Yangde CHEN, William BRONDYK, Huawei QIU, Sunghae PARK, Ronnie WEI, Yu QIU, Yanfeng ZHOU, Cendrine LEMOINE, HyunSuk CHO
Filed: 12 Oct 22
Utility
Flare (Flow Cytometry Attenuated Reporter Expression) Technology for Rapid Bulk Sorting
28 Sep 23
Provided herein are methods and compositions for batch production of producer cells using fluorescence activated cell sorting (FACS).
Victor R. Cairns, Jose Ignacio Sancho Chavida, Christine DeMaria
Filed: 10 Mar 23
Utility
Methods of Processing a Fluid
21 Sep 23
Provided herein are methods of processing a fluid comprising a recombinant therapeutic protein that include the use of a bioprocessing system comprising integrated unit operations, including cell removal, cell retention, chromatography, virus inactivation, virus filtration, TFF, and formulation.
Michael Coolbaugh, Shashi Malladi
Filed: 24 Feb 23
Utility
Gene Therapy for Niemann-pick Disease Type a
14 Sep 23
This disclosure pertains to methods and compositions for tolerizing a mammal's brain to exogenously administered acid sphingomyelinase polypeptide by first delivering an effective amount of a transgene encoding the polypeptide to the mammal's hepatic tissue and then administering an effective amount of the transgene to the mammal's central nervous system (CNS).
Marco A. PASSINI, Robin J. ZIEGLER, James C. DODGE, Lamya SHIHABUDDIN, Seng H. CHENG
Filed: 8 Mar 23
Utility
Analytical Ultracentrifugation for Characterization of Recombinant Viral Particles
14 Sep 23
Provided herein are methods to characterize preparations of recombinant viral particles using analytical ultracentrifugation.
Catherine R. O'RIORDAN, Brenda Burnham
Filed: 22 Mar 23
Utility
Methods for the quantitation of polypeptides
12 Sep 23
Provided are methods for quantitating an amount of a polypeptide that comprises a portion of an antibody present in a sample (e.g., a plasma or serum sample) wherein the antibody comprises a constant region (e.g., a heavy chain or light chain constant region) that comprises an engineered mutation.
Christopher Morgan, Xiaokui Zhang
Filed: 16 Jun 21
Utility
Compositions and Methods for Treating Late-onset Pompe Disease
17 Aug 23
The present application provides methods of treating late-onset Pompe disease (LOPD) using a pharmaceutical composition comprising an oligosaccharide-acid α-glucosidase (GAA) conjugate, such as avalglucosidase alfa.
Patrick FINN, Alaa HAMED, Kristina AN HAACK, Catherine WILSON
Filed: 11 Jun 21
Utility
Eclitasertib for Use In Treating Conditions Involving Systemic Hyperinflammatory Response
27 Jul 23
This disclosure relates to the field of therapeutic protein kinase inhibitors, in particular receptor-interacting protein kinase 1 (“RIPK1”) inhibitor for treatment of subjects with conditions involving systemic hyperinflammatory responses, such as Cytokine Release Syndrome (CRS), or Systemic Inflammatory Response Syndrome (SIRS), sepsis, organ damage, or hyperinflammatory state associated with infectious diseases.
John CAMINIS, Peter FLORIAN, Keith HARRIS, Dimitry OFENGEIM, Sabine SCHNYDER, Heribert STAUDINGER, Matija ZELIC
Filed: 16 Apr 21
Utility
Site-specific glycoengineering of targeting moieties
11 Jul 23
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide.
Luis Avila, Clark Pan, Huawei Qiu, Qun Zhou
Filed: 29 Mar 21